143P Efficacy and safety of aumolertinib (AUM) with radiotherapy versus concurrent chemoradiotherapy (cCRT) in the treatment of unresectable stage III EGFR-mutant NSCLC: A multicenter, randomized, open-label phase III study (ADVANCE)
Title:
143P Efficacy and safety of aumolertinib (AUM) with radiotherapy versus concurrent chemoradiotherapy (cCRT) in the treatment of unresectable stage III EGFR-mutant NSCLC: A multicenter, randomized, open-label phase III study (ADVANCE)
Author:
Bi, N. Wang, J.Y. Jiang, W. Yang, Z. Zhao, L.J. Chen, X.L. Yang, H.H. Qian, D. Shan, G.Y. Wang, H. Fu, X.L. Chen, M. Wang, L.H.